Title : The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer.

Pub. Date : 2021 Oct 6

PMID : 34638488






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. msu42011 retinoid X receptor alpha Homo sapiens
2 Bexarotene, the only FDA-approved RXR agonist, is still used to treat cutaneous T-cell lymphoma. Bexarotene retinoid X receptor alpha Homo sapiens
3 (4) Conclusions: Collectively, these data suggest that the RXR agonist MSU42011 can be used to modulate the tumor microenvironment in breast and lung cancer. msu42011 retinoid X receptor alpha Homo sapiens